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Available online 1 September 2015AbstractVitamin K is a multi-functional nutrient and various tissues modify their function in response to vitamin K bioavailability mainly through
post-translational modification of vitamin K-dependent (VKD) proteins. In this review, we discuss five clinical topics of vitamin K nutrition and
vitamin K-dependent Gla-containing proteins. Although the physiological roles of these VKD proteins need further elucidation, study of these
proteins may open new avenues for therapy in the clinical field. The topics discussed in the review are focused on des-gamma-
carboxyprothrombin (DCP) in relation to the pathogenesis of hepatocellular carcinoma, osteocalcin (OC) and undercarboxylated OC (ucOC)
in relation to bone fractures and insulin sensitivity, matrix Gla protein (MGP) in relation to vascular calcification, and growth arrest-specific
protein-6 (Gas6) in relation to inflammation and platelet aggregation. Finally, interaction among vitamins were discussed.
Copyright © 2015 The Korean Society of Osteoporosis. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Vitamin K is a vitamin known to activate not only blood
coagulation factors, but also tissue-specific vitamin K-depen-
dent (VKD) proteins through post-translational modificationAbbreviations: AAC, aortic artery calcification; ABCC6, large ATP-binding ca
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Insufficient g carboxylated VKD proteins are tissue-specific
sensitive markers for vitamin K insufficiency. Vitamin K ac-
tions are also accomplished via the binding to the nuclear
receptor, SXR. However, until now, useful markers for vitaminssette (ABC) gene subfamily C; AFT4, activating transcription factor 4; Axl,
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in clinical settings. Therefore, vitamin K functions are evalu-
ated by the measurements of tissue-specific VKD proteins in
human studies. One of the typical VKD proteins, osteocalcin
(OC), is considered to be a bone-specific protein and the
function of OC was believed to be protein accretion, which
may stabilize bone hydroxyapatite. The role of OC has been
expanded and it has been shown to be a bone-derived hor-
mone, which regulates energy expenditure. Breakthroughs
regarding the function of vitamin K-dependent proteins in
immunology, inflammation and atherosclerosis have now been
achieved. As a result, several VKD proteins have been inde-
pendently well characterized. However, there is a lack of
knowledge regarding common features of VKD proteins and
of vitamin K nutrition. In this review, the main functions of
each vitamin K-dependent protein are summarized and
possible new biological actions are discussed.
2. Vitamin K-dependent (VKD) proteins as sensitive
markers for vitamin K status
Genetic absence or gene mutations of VKD proteins, di-
etary vitamin K inadequacy, and vitamin K deficiency induced
by chronic anti-coagulant therapy are all linked to age-
associated conditions. For example, bone fragility after
menopause is linked to OC, arterial calcification connected to
cardiovascular disease involves matrix Gla protein (MGP) [1],
while growth arrest-specific protein-6 (Gas6) is related to
thrombotic disease [2] or inflammation.
Table 1 summarizes VKD proteins and their functions.
Hepatic VKD proteins are essential for survival because
bleeding is an immediate threat. Vitamin K preferentially ac-
cumulates in the liver and subsequently vitamin K is trans-
ported to extra-hepatic tissues [3]. Thus, the appearance of
hepatic undercarboxylated VKD is less frequent than the other
organ-specific ucVKDs. Since ucVKD proteins are tissue-
specific, the values of ucVKD proteins such as DCP
(PIVKA II), uncarboxylated-OC (ucOC) and uncarboxylated-Table 1
VKD proteins, functions, markers of vitamin K deficiency and clinical manifestati
proteins were classified by organs where the specific protein was generated. The v
molecule were fully carboxylated or not.
Source Name Function of fully carboxylated VKD protein
Hepatic Prothrombin Pro-coagulant
Factor VII Pro-coagulant
Factor IX Pro-coagulant
Factor X Pro-coagulant
Protein C Anti-coagulant
Protein S Co-factor to protein C
Protein Z Antithrombotic
Extra hepatic Oc Bone formation. Stabilizing bone crystal.
Insulin agonist in humans.
MGP Inhibitor of soft tissue calcification
Gas6 Platelet aggregation. Migration and proliferat
of vascular smooth muscle cells. Thromboe
Inflammation and immune system regulato
VKD: Vitamin K-dependent, DCP: des-gamma-carboxyprothrombin, OC: osteocalMGP (ucMGP) are indicators of tissue-specific vitamin K
bioavailability [4] in liver, bone and vessels, or cartilage,
respectively. Gas6 (growth arrest-specific protein 6) plays
important roles in a variety of organs such as vessels, fat tissue
and brain as mentioned in the latter part of the review. How-
ever, until now, there has been no report on whether ucGas 6
shows significant clinical manifestations.
Using such sensitive markers in a depletion-repletion study,
Booth et al. [5] established that a vitamin K-restricted diet
taken by volunteers for 15 days resulted in a sufficient
lowering of tissue stores of vitamin K, which caused an in-
crease in DCP and %ucOC (ratio of ucOC to intact (c)OC).
The increase in ucVKD proteins after vitamin K depletion was
reversed by a subsequent 10-day repletion phase with vitamin
K1 at a dose of 200 mg/day [5]. Therefore, vitamin K depletion
and repletion in tissues was achieved with intake of a vitamin
K deficient or sufficient diet, respectively.
3. Clinical topics of ucVKD/cVKD proteins3.1. PIVKA II (protein induced by vitamin K absence II)
or des-g-carboxyprothrombin (DCP) in hepatocellular
carcinomaDes-g-carboxyprothrombin (DCP) is known as a marker of
hepatocellular carcinoma (HCC) [6]. Excessive production of
DCP is associated with tumor expansion or metastasis of HCC.
Therefore, DCP is a good marker for the diagnosis of HCC
and is a predictor of the prognosis in patients bearing HCC.
Although several causes of the production of DCP in HCC
cells have been postulated, the exact mechanism(s) of how
DCP is produced by HCC cells is yet to be confirmed. Four
possible mechanisms may be involved in the DCP production
process. First, low g-glutamyl carboxylase (GGCX) activity
was observed in a rat model of Morris hepatoma tumor [7].
Vitamin K epoxide reductase subunit C1 (VKORC1) haplo-
types also influenced the performance characteristics of DCP
for screening hepatocellular carcinomas [8]. Second, theons. The vitamin K dependent proteins were summarized in the Table 1. The
itamin K dependent proteins were also classified whether Glu residues in the
Vitamin K deficiency Function of under- carboxylated
VKD protein
DCP (PIVKAII) Hepatoma
ucOC Fracture. Insulin stimulant
ucMGP Calcification of vessel or cartilage.
ion
mbolism.
r
ucGas6 ? ?
cin, MGP: matrix-Gla-protein, Gas6: growth arrest-specific gene 6.
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et al. [9] reported that a HCC cell line produced DCP in a
time- and cell number-dependent manner in the absence of
vitamin K, but not in the presence of vitamin K. This finding
clearly indicated that DCP production is enhanced by vitamin
K insufficiency in HCC cells. Third, DCP production is not a
specific event in HCC since severe vitamin K deficiency in
normal hepatic cells also produced DCP [5]. However, the
amount of DCP produced in normal cells is less than HCC
cells. Therefore, tumor-specific metabolic processes such as
hypoxia may stimulate DCP production. Fourth, excessive
production of the pro-thrombin precursor was observed in
HCC cell lines [10] and excess pro-thrombin precursor may
lead to excessive DCP production.
Since DCP is associated with HCC growth and metastasis,
it is reasonable to expect that vitamin K supplementation may
have a beneficial effect on HCC. Another possible role of
vitamin K in suppression of HCC has been reported. Over-
expression of SXR in vitamin K2 treated HCC cell (HuH17)
resulted in reduced proliferation and motility of the cells.
These results suggest that the activation of SXR could
contribute to tumor suppressive effects of vitamin K2 on HCC
cells [11].
In fact, an open label randomized study regarding vitamin
K2 effects on curative recurrence-free rates in patients withFig. 1. (A) The effect of MK-4 administration on serum levels of IOC. Serum lev
controls. Black and gray bars indicate the MK-4 and the control groups, respectively
4 induced a significant increase in serum cOC 1 month after treatment and thereafter
ucOC levels. MK-4 induced a significant decrease in serum ucOC 1 month after tre
cited from ref. number 18 with modification. MK-4: menaquinone-4, IOC: in
osteocalcin.HCC revealed that vitamin K2 significantly suppressed the
recurrence of HCC [12,13]. However, a double blinded
placebo-controlled study between the groups with vitamin K2
and placebo failed to reduce the recurrence of HCC and to
prolong survival [14]. This study ignored the baseline vitamin
K nutritional state of the participants. Since vitamin K2 may be
expected to have beneficial effects only in vitamin K-deficient
subjects, trials should be focused on patients with low vitamin
K intake.
In conclusion, vitamin K deficiency or insufficiency in-
duces production of DCP in patients with HCC and this
biomarker is useful to monitor HCC growth and metastasis.
However, vitamin K nutrition in the assessment of blood levels
of DCP will be required. Although the intervention of vitamin
K failed to show beneficial effects in patients with HCC,
further clarification of the role of vitamin K on the progression
of HCC may be necessary.3.2. Undercarboxylated osteocalcin (ucOC)/
carboxylated osteocalcin (cOC)
3.2.1. Determinants of g-carboxylation in OC
OC is a bone-specific vitamin K-dependent protein and is
synthesized by osteoblasts during the latter phase of bone
calcification [15]. Osteocalcin is the most abundant non-els of IOC after 6 months treatment of MK-4 were significantly higher than
. *; P < 0.006 vs control. (B) The effect of MK-4 treatment on cOC levels. MK-
. *; P¼ 0.018, #: P < 0.001 versus control. (C) The effect of MK-4 treatment on
atment and thereafter. $; P ¼ 0.002, #: P < 0.001 versus control. The data were
tact osteocalcin, cOC: carboxylated osteocalcin, ucOC: Undercarboxylated
25M. Shiraki et al. / Osteoporosis and Sarcopenia 1 (2015) 22e38collagenous protein in bone and its concentration in blood is
tightly connected to osteoblast function, differentiation and
vitamin K sufficiency. OC contains three Glu residues in the
molecule, which need vitamin K-dependent post-translational
g-carboxylation to Gla residues. The post-translational modi-
fication of OC is regulated by several factors. The strongest
regulator of carboxylation is vitamin K intake from food
[16e21]. Administration of vitamin K homologues (Phyllo-
quinone/Vitamin K1 [22,23], Menaquinone-4 (MK-4) [24e26]
and Menaquinone-7 (MK-7) [27,28] enhanced the carboxyla-
tion process. Both dietary intake of vitamin K [5] and phar-
macological dose of MK-4 [24] induced rapid alteration of g-
carboxylation of Glu residues in OC molecules. Fig. 1 shows
the effect of MK-4 treatment on serum levels of intact
osteocalcin (IOC) (Fig. 1a), Gla-OC (Fig. 1b) and ucOC
(Fig. 1c). A rapid increase in Gla-OC and concomitant
decrease in ucOC within 1 month after the MK-4 adminis-
tration, and a subsequent increase in IOC 3e6 months after
treatment, were observed [24]. These findings might indicate
that MK-4 administration induced rapid enhancement of g-
carboxylation and at the latter phase, MK-4 may induce OC
expression from osteoblasts.
Since serum levels of vitamin K1 are negatively correlated
with ucOC/IOC ratio in postmenopausal women [19], the ratio
of ucOC to IOC (ucOC/IOC) is a sensitive marker for the
sufficiency of vitamin K in bone. Carboxylation efficiency is
deteriorated by advancing age. The regression line between
plasma vitamin K1 levels and the ucOC/IOC ratio in the older
group shifted toward a higher ucOC/IOC ratio at a given
serum vitamin K1 level [21] (Fig. 2). This means that older
people require more vitamin K than younger people in terms
of g-carboxylation of OC. The reasons why the vitamin K
requirement is increased with aging are discussed below. Bone
turnover rate or the bone remodeling process may influence
the ucOC/IOC ratio. Children, who have a very high turnover
rate of bone, showed markedly higher levels of the ucOC/IOC
ratio than healthy adults [27,29]. In contrast, treatment of
bisphosphonate in osteoporotic patients induced a larger
reduction of serum ucOC than other bone markers suggestingFig. 2. The age-dependent difference in the relationship between plasma
phylloquinone concentration and serum ucOC/IOC ratio. A significant in-
crease in the ucOC/IOC ratio at a given level of plasma vitamin K1 was
observed with increasing chronological age [21]. ucOC: Undercarboxylated
osteocalcin, IOC: intact osteocalcin.that suppressed bone turnover with bisphosphonate treatment
was linked to enhanced carboxylation of OC [30] or lowered
vitamin K requirement of bone [26]. Therefore, the bone
requirement of vitamin K may depend on the rate of bone
turnover.
A second possible explanation is the change in the enzy-
matic activity of gecarboxylase as age advances. The meta-
bolic vitamin K cycle involves VKORC1 and GGCX. These
two key enzymes in the vitamin K cycle are critically
responsible for the biological activity of vitamin K. Thus, it is
possible that aging might influence enzymatic activities.
However, the mechanistic details that may be involved in
aging have not yet been elucidated.
These two key enzymes are known to have functionally
relevant gene polymorphisms and the efficiency of the vitamin
K cycle depends on these gene polymorphisms. Therefore, it
can be hypothesized that functionally relevant polymorphisms
of these enzymes modulate the inverse relationship between
dietary vitamin K intake and serum ucOC [18,31,32]. Table 2
summarizes the confirmed determinants of g-carboxylation in
the OC molecule.
3.2.2. Undercarboxylated osteocalcin (ucOC),
carboxylated osteocalcin (cOC) and bone fractures
g-carboxylated Gla residues are responsible for the specific
affinity of OC to the hydroxyapatite (HAP) molecule [33,34].
As a result, Gla-containing osteocalcin (cOC) normalizes bone
crystal nucleation [34]. The bone phenotype of OC knockout
mice (OC/) had higher bone formation than wild-type (WT)
mice. Bone strength was also superior in OC/ mice than in
WT mice. However, bone mineral density (BMD) in OC/
mice was decreased rapidly after ovariectomy suggesting that
OC modulates bone formation to protect from hyper-
mineralization and rapid bone loss after menopause [35]. In
addition to the OC/ mice, long-term warfarin-treated rats
showed higher bone mineral content (BMC), bone area, and
cortical thickness (Cth) than controls [36]. This suggests that
long-term OC deficiency in bone caused increased bone size.
Ovariectomy in long-term warfarin-treated rats induced a
significantly faster reduction in BMD, bone area and Cth than
controls [36]. Therefore, OC-deficient bone shows hyper-
mineralized bone before menopause, but bone is rapidly
reduced when estrogen is lacking.
In 1985, Hart et al. first reported low serum vitamin K1
levels in patients with hip fractures [37]. Several subsequent
studies also reported that low vitamin K intake was associated
with hip or vertebral fractures both in Caucasian and Asian
populations [38e45]. Tanaka et al. reported that bone OC
content in patients with hip fractures was significantly lower
than controls who had osteoarthritis [46]. In addition to the
deterioration of vitamin K nutrition in hip fracture patients, the
close relationship between vitamin K-dependent proteins and
incident fractures has been reported extensively. Szulc et al.
first reported that serum levels of ucOC were higher in patients
with hip fractures than controls [47]. Moreover, serum levels
of ucOC predicted future fractures in elderly people [48e50]
and even in osteoporosis patients treated with
Table 2
Determinants of g-carboxylation of osteocalcin. The determinants of g-
carboxylation of osteocalcin molecule were listed. Each determinant was
proofed by the literature cited in the table.
1. Dietary intake of vitamin K [16e21]
2. Supplementation of vitamin K1, MK-4 and MK-7 [22e28]
3. Aging [21]
4. Bone turnover [27,29,30]
5. Changes in enzymatic activities including gene polymorphisms of
VKORC1 and GGCX [20,31,32]
6. Warfarin use
MK: menaquinone, VKORC1: vitamin K epoxide reductase, GGCX: g-glu-
tamyl carboxylase.
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incident fractures in patients treated with bisphosphonate
(alendronate). Higher ucOC level (>2.5 ng/ml) at the end of
observation was an independent risk for fractures during
treatment [51]. Therefore, it is consistent that ucOC is a useful
marker for the prediction of incident fractures of the hip or
vertebrae. Although a consistent relationship between ucOC
and fractures has been repeatedly reported, it is still unclear
whether bone fractures in vitamin K deficiency can be
explained only by loss of OC function in bone.
Recently, it has been reported that vitamin K binds to the
xenobiotic nuclear receptor (SXR/PXR) leading to enhanced
expression of several components of the bone matrix [52,53].
Furthermore, systemic SXR/PXR knockout mice displayed
marked reduction in bone mass through reduction of bone
formation together with increase in bone resorption [54].
These reports indicated that vitamin K is a transcriptional
regulator of extracellular matrix-related genes, some of which
are involved in collagen assembly [53]. However, in contrast
to steroid receptors such as estrogen receptor, which binds to
estrogen specifically, the SXR/PXR can bind to endogenous or
exogenous toxic chemicals to reduce their toxicity. This means
that the phenotypes of SXR/PXR knockout mouse not only
exhibit loss of function of vitamin K but also shows loss of
function of the other kinds of ligands. Moreover, vitamin K
might inhibit bone resorption through inhibition of prosta-
glandin production in an organ culture system [55] and
vitamin K2 stimulated osteoblastogenesis and suppressed
osteoclastogenesis [56,57] by suppressing NF-kB activation
[58]. However, it has been still not elucidated whether theTable 3
Risk factors for incident vertebral fractures in patients treated with
bisphosphonates.
Risk X2 P R2
Number of prevalent vertebral fractures 21.999 0.0000 0.0772
Age (y) 9.1164 0.0025 0.1092
ucOC after treatment (in ng/ml) 4.4385 0.0351 0.1247
Lumbar BMD (in g/cm2) 3.8923 0.0458 0.1384
Multiple logistic regression analysis was retrospectively performed on 231
osteoporotic women treated with alendronate. Significant risk factors for
incident fracture are listed in the table. ucOC level during treatment was an
independent risk for the incident fractures. The cut-off level of ucOC was
2.5 ng/ml suggesting that higher ucOC levels during bisphosphonate treatment
are a predictor of future fractures [51]. ucOC: undercarboxylated osteocalcin,
BMD: bone mineral density.effects of vitamin K on bone metabolism is a reflection of
SXR/PXR mediated process or not. The SXR-mediated
metabolic effects of vitamin K on bone could not be
assessed clinically because there are no biological marker(s)
that reflect vitamin K actions via a nuclear receptor. Effects of
vitamin K on osteoblastogenesis may be explained by
increased OC levels after vitamin K2 administration [24].
However, other evidence of vitamin K effects on osteoclas-
togenesis or osteoblastogenesis, or on collagen metabolism, in
humans has not been established clinically.
3.2.3. Effects of vitamin K treatment on bone
There are several reports regarding vitamin K intervention
trials on bonemarkers, bonemineral density (BMD) and fractures.
Table 4 summarizes the findings of the 9 articles that met the
inclusion criteria mentioned at the table legend. From these
studies, it might be concluded that vitamin K administration
did not reduce bone resorption markers, but did reduce ucOC in
both postmenopausal women and osteoporotic women. How-
ever, changes in total OC concentration after vitamin K treat-
ment were inconsistent among the reports. The change in BMD
after vitamin K administration was also found to be inconsis-
tent. A meta-analysis indicated that modest overall treatment
effects for vitamin K on BMD were observed, but the reports
had significant bias. Therefore, the effects of vitamin K on
BMD should be interpreted with caution [67].
The reported data are also inconsistent in regard to the
effect of vitamin K on bone fractures, as shown in Table 4. The
most surprising observation was the Osteoporotic Fracture
study (OF study) [65], in which the incidence of fracture be-
tween the control and the vitamin K2-treated groups did not
differ significantly (RR 1.03, 95% confidence interval was
0.87e1.22). However, another two trials [59,63] showed a
significant reduction in incident fracture rate in vitamin K2
[59] and K1 [63]-treated groups. The reason(s) for these
disparate results is uncertain. The meta-analysis indicated that
several plausible factors may account for the discrepancy in
results in the OF study. There was a less specific diagnostic
criteria for osteoporosis and incident fracture [68], and a very
low incident fracture rate in the control group (13.6% during 3
years). This suggested that there was an inadequate count of
incident fracture occurrence [68,69].
It has been reported that vitamin K2 administration either
with calcium and risedronate [70], or vitamin K2 with vitamin
D plus calcium [71], significantly reduced non-vertebral
fractures in Alzheimer's disease, which is a disease known to
have significantly higher rates of hip fractures [72]. In addition
to Alzheimer's disease, fractures in Parkinsonism and cere-
brovascular disease were also reduced by the administration of
vitamin K2 [73]. Therefore, it might be tentatively concluded
that vitamin K has some beneficial effect on bone health
probably through reduction of ucOC.
Vitamin K intake has large demographic differences [37].
Elderly people [74] living in institutions [75] showed a higher
susceptibility to vitamin K deficiency. These subjects may be
good candidates to evaluate the anti-fracture efficacy of
vitamin K [76]. Children, who have very high bone turnover
Table 4
Effects of vitamin K intervention on bone.
Author
(Abbr St name)
Y Subjects Reference
group (no)
Test group (no) Obser-
vation
BTM BMD Fracture
Shiraki [59] 2000 PMO Ca (121) K2 45 mg (120) 2 y No DIF in DPD.
Decrease in ucOC.
Sustained RR 0.44
Braam [60] 2003 PMW D þ Ca (124) K1 1 mg (133) 3 y No DIF in DPD. Sustained N/A
Knappen [61] 2007 PMW No (124) K2 45 mg (133) 3 y Increased OC. No DIF
in DPD & NTX.
Improved femur geometry N/A
Bolton-Smith [62] 2007 PMW Placebo (61)
D þ Ca (62)
K1 (60) K1 þ
Ca þ D (61)
2 y Decreased ucOC.
Increased GlaOC
in K groups.
Decreased PTH in
D groups
No DIF in K1 and placebo
K1 þ Ca þ D group.
Significant increase in
radial BMD
N/A
Cheung [63]
(ECKO)
2008 Osteopenia Placebo (202) K1 5 mg (198) 2 y No DIF in CTX.
Decrease in %
ucOC
No DIF in BMDs at
any sites
RR 0.45
Booth [64] 2008 Men and
PMW
D þ Ca (223) K1 500 mg (229) 3 y Decrease in %ucOC.
No DIF in OC,
NTX.
No DIF in BMDs
at any sites
N/A
Binkley [22] 2008 PMW D þ Ca (129) K1 1 mg (126)
K2 45 mg (126)
1 y Decrease in %ucOC
and total OC. No
DIF in NTX, BAP
No DIF in BMDs, geometry
or US parameters
N/A
Inoue [65]
[OF study]
2009 OP Ca (2016) K2 45 mg (1999) 3 y N/A N/A Overall ns.
Multiple fracture
RR 0.61
Emaus [66] 2010 PMW Placebo (153) MK-7360 mg (153) 1 y ucOC decreased. cOC
increased. N-mid
OC decreased
No DIF at any
sites of bone
N/A
Abbr St name: abbreviated study name, No: number, BTM: bone turnover markers, BMD: bone mineral density, K1: vitamin K1, PMO: postmenopausal oste-
oporosis, Ca: calcium, D: vitamin D, DIF: difference between control and test drugs, RR: relative risk, PMW: postmenopausal women, N/A: not applicable, DPD:
deoxypyridinoline, NTX; n-telopeptide of type I collagen, CTX: c-telopeptide of type I collagen, US: ultrasound, BAP: bone-derived alkaline phosphatase, OP:
osteoporosis, ns: not significant.
The selection criteria of the literature are as follows.
1) Subjects: Healthy volunteers or postmenopausal osteoporosis patients.
2) Method of intervention: Randomized placebo or no treatment controlled prospective study.
3) Number of subjects: Over 50 participants per group.
4) End points: Bone markers, BMD or incident fractures.
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to assess vitamin K benefits on bone. Although serum ucOC
concentration in puberty, where bone turnover is increased, is
much higher than in adults, a clear association is observed
between vitamin K status and serum ucOC concentration in
puberty [77]. Van Summeren et al. reported an improvement of
vitamin K status over 2 years that was associated with a
marked increase in total body BMC in peri-pubertal children
[29,78].
3.2.4. ucOC and bone in warfarin users.
Since many epidemiological studies indicated that vitamin
K deficiency in bone was connected to the incidence of bone
fracture in humans, it is reasonable to expect that patients
treated with warfarin might have a higher susceptibility to
bone fractures. However, divergent results have been reported
regarding warfarin use and low BMD or fracture risk. Binkley
et al. reported long-term warfarin treatment altered neither
serum bone turnover markers, urinary excretion of calcium nor
BMD despite an increase in ucOC in male rhesus monkeys
[79]. Jamal et al. first reported the effects of warfarin treatment
on bone health in 149 warfarin users versus 6052 non-users.
There was neither a significant difference in BMD at the hipor heel, nor was there a difference in the fracture incidence
between patients with and without warfarin treatment [80].
Another two studies also reported negative results in fracture
risk with warfarin treatment [81,82]. On the other hand, Car-
aballo et al. reported a significant increase in fracture risk of
vertebrae and ribs in long-term warfarin treated patients in a
time-dependent manner [83]. Two other studies also reported a
positive association [84,85]. These studies used a nationwide
study design suggesting that a caseecontrol study between
warfarin users and non-users needs a huge number of subjects
because of the presence of numerous confounding factors.
Generally, warfarin users may have lower physical activity,
frailty and existing comorbidities, which are all additional
potential risks for fractures. Therefore, the increased risk of
fractures in warfarin users may be over-estimated. Recently,
anti-coagulants that do not affect vitamin K metabolism have
become available and it is now possible to investigate whether
warfarin affects bone health or not by comparing patients
treated with these new anti-coagulants such as dabigatran. Past
research suggested that the bone status of warfarin users
should be carefully assessed and patients should be guided as
to the proper dietary interventions concerning calcium and
vitamin D to maintain bone health [86]. A recent large-scale
Table 5
Summary of the clinical investigations on the relationship between vitamin K or osteocalcin and glucose or fat metabolism. The literature demonstrated the relationship between vitamin K or osteocalcin and
glucose or fat metabolism in human study, were summarized in the table. A total of 30 references were cited and the design of the studies were mostly consisted of cross-sectional study. Some of them were
intervention study using vitamin K administration.
Author (ref. No.) Year Method Subjects Results
Sakamoto [99] 2000 Intervention using MK-4 (90 mg/day) for 1 week on
glucose tolerance test
Healthy male divided by the serum level of DCP IRI response at glucose load improved after MK-4
treatment in the high baseline DCP group.
Im [101] 2008 Cross-sectional study PMW (339) Quartile analysis using t-OC level t-OC correlated with plasma glucose, HbA1c and insulin
resistance
Yoshida [102] 2008 Cross-sectional study (Framingham Offspring
Cohort)
1247 men and 1472 women Higher vitamin K1 intake was associated with greater
insulin sensitivity and glycemic status.
Yoshida [103] 2008 Intervention using vitamin K1 500 mg/day versus
control in elderly non-diabetic subjects. End point
was HOMA-IR.
95 men and 134 women received vitamin K, and
90 men and 133 women were given no
supplementation.
Vitamin K1 improved HOMA-IR in men at 36 months, but
not in women.
Kindblom [104] 2009 Cross-sectional study (MrOS Sweden study) Non-DM (857) T2DM [153] t-OC related with BMI, fat mass, FPG.
Shea [105] 2009 Cross-sectional and longitudinal (3- year
observation)
Non-DM (348 men & women) ucOC not associated with HOMA-IR.
cOC and tOC were associated with lower insulin
resistance. Baseline cOC was associated with a 3-year
change in HOMA-IR.
Hwang [106] 2009 Cross-sectional 199 men (mean age, 47 years) cOC and ucOC were associated with improved glucose
tolerance.
Pittas [107] 2009 Cross-sectional and longitudinal (3 years
observation)
199 men and 246 women (mean age, 71 years) tOC was associated with FPG, fasting insulin, insulin
resistance, hCRP, IL-6, BMI and body fat. NTX showed
no relationship.
Kanazawa [108] 2009 Cross-sectional 179 men and 149 women with or without T2DM tOC was associated with FPG, HbA1c, %Fat, baPWV, IMT
and adiponectin.
Kanazawa [109] 2009 Intervention on glycemic control ucOC/tOC were measured in 50 poorly
controlled T2DM before and after glycemic
control.
tOC was increased and ucOC/tOC ratio was decreased after
glycemic control.
Zhou [110] 2009 Cross-sectional 254 men and 246 women with or without T2DM tOC correlated with glucose and fat metabolic parameters.
Fernandez-Real [111] 2009 Cross-sectional and a dietary and exercise
intervention study
149 men for cross-sectional study. In the
intervention study, control (n ¼ 7), diet
induced weight loss (n ¼ 8) and weight loss by
diet þ exercise (n ¼ 11) in obese subjects
Cross-sectional: tOC positively correlated with insulin
sensitivity. Intervention study: Diet þ Exercise group
showed increase in tOC with improvement in fat
metabolism.
Pan [112] 2009 Cross-sectional 5800 participants to NHANES, aged 20e45.
Association study between PK1 intake and
MetS.
Low dietary intake of PK1 is associated with
hyperglycemia.
Gast [113] 2009 Prospective 16,057 female participants in the Prospect-EPIC
cohort Vitamin K intake and CHD incidence
Dietary intake of Vitamin K2 was associated with CHD
Saleem [114] 2010 Cross-sectional 1284 black and 1209 white. Association study
between tOC and MetS
Highest OC level was associated with a low prevalence of
MetS regardless of race.
Prats-Puig [115] 2010 Cross-sectional Population-based healthy prepubertal children
(n ¼ 103)
ucOC/tOC ratio was associated with HOMA-b and
adiponectin.
Winhofer [116] 2010 Cross-sectional Pregnant women (n ¼ 78) tOC was higher in gestational diabetic women than normal
glucose tolerance pregnant women.
Yeap [117] 2010 Cross-sectional Population based cohort of men aged over 70
years (n ¼ 2765).
tOC and components of MetS
tOC was associated with the components of MetS
Kumar [118] 2010 Intervention with 1 mg of vitamin K1 for 12 months
on insulin secretion and resistance.
End points: ucOC, insulin secretion and
resistance.
Changes in ucOC concentration do not alter glucose
metabolism.
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Bao [119] 2011 Cross-sectional Men who underwent coronary angiography
(n ¼ 181)
tOC was lower in MetS and CHD.
Kanazawa [120] 2011 Intervention on glycemic control T2DM (n ¼ 50) End point: Changes in glycemic
control and tOC.
Change in tOC correlated with changes in HbA1c, TG,
HDL-Cholesterol. tOC change also correlated with
atherosclerotic index in T2DM.
Iglesias [121] 2011 Cross-sectional 64 obese patients. End points: bone markers and
glucose tolerance test
tOC only was correlated with glucose tolerance, but other
bone parameters were not.
Tan [122] 2011 Cross-sectional 2344 men (20e69 years) tOC is associated with MetS and the components.
Kanazawa [123] 2011 Cross-sectional 180 men and 109 PMW. End points: Correlation
between bone markers and diabetic parameters
and fat mass.
ucOC is associated with plasma glucose and fat mass.
Kanazawa [124] 2011 Cross-sectional 101 PMWand 152 men with T2DM. End points:
The relationship between tOC and glycemic
control and adiponectin levels.
tOC is associated with insulin sensitivity and secretion in
T2DM.
Knapen [125] 2011 Cross-sectional intervention using placebo and MK-
7 for 12 Wks in 42 young people, and intervention
using MK-4 and placebo for a 3-year study on
adiponectin and body weight.
Cross-sectional study in 244 PMW. cOC correlated with body weight, BMI and fat mass. But
VK status and adiponectin level showed no significant
relationship. MK-4 treatment group maintained body
weight, but the placebo group gained weight.
Schafer [126] 2011 Intervention using alendronate and PTH (n ¼ 97) Comparative study between alendronate
(n ¼ 33) and daily PTH (n ¼ 64). End point:
Changes in ucOC, body fat and glucose
metabolism.
PTH treatment induced the increase in ucOC, while
alendronate treatment decreased ucOC. The change in
ucOC correlated with the changes in body weight, fat
mass and adiponectin.
Rochefort [127] 2011 Intervention 27 pre-pubertal obese children with or without
physical training.
Physical training increased BMD and OC. Insulin was
lowered by training.
Hwang [128] 2012 Cross-sectional 425 subjects. tOC, glycemic status and
adiponectin.
tOC level is associated with improved glucose tolerance and
insulin sensitivity and secretion independently from
adiponectin.
Levinger [129] 2014 Exercise Intervention 11 obese men tOC and ucOC before and after
exercise
ucOC was increased, while glucose decreased. No change
in tOC phosphorylated Akt. AS160 in muscle increased.
IRI: immunoreactive insulin, PMW: post-menopausal women, tOC: total osteocalcin, cOC: carboxylated osteocalcin, non-DM: subjects without diabetes mellitus, T2DM: type 2 diabetes mellitus, BMI: body mass
index, FPG: fasting plasma glucose, HOMA-IR: homeostasis model assessment of insulin resistance. HOMA-b: homeostasis model assessment of b-cell function (insulin secretion), hCRP: high sensitive C-
reactive protein, IL-6: interleukin-6, NTX: type I collagen cross-linked N-telopeptide, baPWV: brachial-ankle pulse wave velocity, IMT: intima-media thickness, NHANES: National Health and Nutrition Survey,
CHD: coronary heart disease, TG: triglycerides.
2
9
M
.
S
h
ira
ki
et
a
l.
/
O
steo
p
o
ro
sis
a
n
d
S
a
rco
p
en
ia
1
(2
0
1
5
)
2
2e
3
8
30 M. Shiraki et al. / Osteoporosis and Sarcopenia 1 (2015) 22e38randomized comparative study between dabigatran and
warfarin patients indicated that stroke and the risk of bleeding
were reduced in the dabigatran-treated group regardless of
INR (International Normalized Ratio) values [87]. Thus, it is
possible that the new alternative treatments may have benefi-
cial effects on bone health compared to warfarin treatment
[87]. Warfarin use during gestation has been reported to have
skeletal and central nervous system abnormalities called as
warfarin embryopathy (DiSaia syndrome) [88]. The skeletal
manifestation of warfarin embryopathy was nasal hypoplasia,
and calcific stippling of secondary epiphyses. It is difficult to
distinguish the cause of these manifestations owed to
congenital malformations or to drug induced one. Inhibition of
calcium binding of osteocalcin during a critical period of
ossification, could explain the nasal hypoplasia and stippled
calcification seen in the warfarin embryopathy [88]. However,
these manifestations are quite different from the findings of
osteocalcin knockout mouse [35]. Therefore, the congenital
elimination of osteocalcin and the lack of carboxylated
osteocalcin during development may display different
manifestations.
3.2.5. ucOC and pancreas and fat cell loops in a mouse
model.
Ducy et al. generated OC/ mice [35] and they found an
abnormal amount of visceral fat and glucose intolerance in the
mutant mice. Furthermore, Lee et al. found that OC could
stimulate Cyclin D1 in b-cells and insulin and adiponectin
expression in adipocytes [89]. UcOC, which is generated
through decarboxylation of cOC stored in bone [89], was more
potent at inducing adiponectin and insulin secretion than cOC
in cultured WT fat cells and islet cells, respectively [90]. In
addition, the same group generated osteoblast-specific insulin
receptor deficient mice (InsR osb
/ mice). Interestingly, InsR osb
/
mice indicated that insulin signaling in osteoblasts was a
determinant of whole body glucose metabolism [90]. This
finding is evidence of the presence of a bone-pancreas endo-
crine loop. Furthermore, InsR osb
/ mice had a marked decrease
in the serum levels of the collagen type I cross-linked C-
telopeptide (CTx), which is a marker for bone resorption. Bone
formation parameters in bone histology were severely
decreased in InsR osb
/ mice. As a result, these mice had low
bone mass [90].
Recombinant ucOC from bacteria was used to evaluate the
effects of ucOC on islet b-cell and adipocyte gene expression.
Physiological concentration of ucOC (picomolar) increased
expression of insulin genes and b-cell proliferation, whereas
nanomolar amounts of ucOC induced adiponectin expression,
an adipokine that enhances insulin sensitivity, and genes
regulating energy expenditure in white and brown adipocytes,
respectively [91]. Pi et al. found that GPRC6A (G-protein
coupled receptor family C, group 6, member A) is a candidate
receptor for mediating the effects of OC on insulin secretion in
the pancreas [92,93]. Since GPRC6A is a widely expressed
protein located in various cell membranes and senses amino
acids and extracellular calcium [93,94], GPRC6A may not
only participate in the bone-pancreas hormone loop, but mayalso be involved in anabolic actions in multiple tissues [95].
As for transcriptional factors in this bone-pancreas loop,
forkhead family transcription factor (FoxO1) and activating
transcription factor 4 (AFT4) were reported to be key modu-
lators [96,97]. These experiments using mouse models have
shown that OC is a bone-derived hormone affecting glucose
levels through insulin secretion and sensitivity. OC was also
shown to increase energy expenditure at least in the mouse.
3.2.6. Osteocalcin-insulin relationship in humans
[98e129]
In 1999, Sakamoto et al. reported that a low vitamin K diet
induced glucose intolerance in rats [98]. Subsequently, an
intervention trial in young male volunteers using
menaquinone-4 (MK-4) at a dose of 90 mg/day for 1 week was
performed [99]. MK-4 increased the immunoreactive insulin
(IRI) response in pre-existing vitamin K-deficient subjects
[99]. Furthermore, vitamin K1 or MK-4 administration in rats
induced a significant reduction in fat accumulation with
increased BMD [100]. No researchers followed up on these
reports until the publication of Lee et al. [89]. After publishing
reports about the skeleton-pancreas loop, it has been ques-
tioned whether OC levels are associated with glucose and/or
fat metabolism in humans.
In a rodent model, it has been clearly shown there is a close
relationship between OC or vitamin K levels and glucose and
fat metabolism. In humans, a similar relationship has been
partly demonstrated. In Table 5, we have summarized the
literature that investigated the roles of vitamin K or OC on fat
and glucose metabolism. Almost all of the investigations
support the hypothesis in rodent models that ucOC secretion
from bone stimulates glucose tolerance through enhanced in-
sulin secretion and sensitivity, or fat metabolism. However, in
contrast to the rodent models, cOC or tOC may also have a
close relationship with fat or glucose metabolism in humans.
In a rodent model, Lee et al. [89] found that the embryonic
stem cell protein (Esp) gene plays a key role in the OC-
pancreas relationship. When the Esp gene was deleted in
mice (Esp/), the phenotype of this mouse was completely
opposite to that of OC/ mice. Esp/ mice showed lower
plasma glucose, higher insulin secretion and higher insulin
content in b-cells through increasing ucOC. The authors hy-
pothesized that osteotesticular protein tyrosine phosphatase
(OST-PTP) was responsible for inactivating ucOC through g-
carboxylation [89]. However, the Esp gene does not produce a
functional product in humans [130]. Therefore, the meta-
bolism of OC in humans may differ from rodents and the role
of OC on insulin or fat mass may also differ.
In many cross-sectional studies, OC was clearly correlated
with glycemic control or the size of body fat mass. If the OC
de-carboxylation process is responsible for improvement of
glucose intolerance or of fat mass in humans, vitamin K
treatment or inhibition of de-carboxylation of OC may have
negative effects on glucose or fat metabolism. In the inter-
vention studies listed in Table 4, however, the effects of using
vitamin K or dietary intake of vitamin K did not provide clear
results compared to the cross-sectional studies and they were
Fig. 3. Roles of vitamin K and osteocalcin on various tissues. The role of
vitamin K and osteocalcin on bone, fat cell and pancreas were summarized in
the figure. There are two platforms on the action of vitamin K. The first
platform is the process via nuclear receptor (SXR/PXR) binding to generate
collagen assembly proteins, which may stabilize bone mineral probably
together with osteocalcin. The second platform is conducted by osteocalcin
activation by GGCX and osteocalcin (ucOC or OC) binds to GPRC6A to
transduce the OC signal into fat cells and pancreatic cells, in order to generate
adiponectin and insulin, respectively. These metabolic processes via osteo-
calcin may contribute to beneficial effect on glucose metabolism. GGCX: g-
glutamyl carboxylase, GPRC6A: G-protein coupled receptor family C.
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carried out in the general population or in patients with dia-
betes or obesity regardless of vitamin K status, which may
partly explain this discrepancy. A previous report [98] indi-
cated that the beneficial effect of vitamin K2 on insulin
secretion during glucose load was significant only in subjects
with a vitamin K deficiency. Thus, future investigations on
whether vitamin K intervention has direct effects on glucose or
fat metabolism should be carried out in patients divided into
groups based on their vitamin K status.
In addition to these intervention studies, the effects of
warfarin treatment on glucose metabolism should also be
investigated. Since warfarin does not affect bone turnover,
warfarin effects are probably limited to the carboxylation
process in OC. If the rodent model is applicable to humans, it
is expected that warfarin treatment may have a beneficial ef-
fect on glucose metabolism because warfarin treatment
markedly increases serum ucOC. However, until now, there is
no available data investigating the beneficial effects of
warfarin on glucose metabolism.
In the treatment of osteoporosis, Schafer et al. [126] re-
ported the relationship between changes in ucOC and body
weight among the patients treated with alendronate or 1e84
parathyroid hormone (PTH). Participants who received PTH
treatment experienced a small but significant decrease in mean
body weight over 12 months (0.8 Kg, 95% CI -1.5 to
0.1 Kg, p ¼ 0.03). Conversely, those in the alendronate
group had no significant change in weight. ucOC levels in the
PTH and alendronate groups demonstrated a 242% increase
and 29% decrease, respectively. Therefore, changes in ucOC
or tOC induced by osteoporosis treatment may induce weight
change. A recent study focused on the role of ucOC on skeletal
muscle, a modulator of glucose metabolism. Levinger et al.
reported that exercise increased serum ucOC levels, but not
tOC, concomitant with lower blood glucose and an increase in
insulin sensitivity in obese men [129].
In summary, the relationship between ucOC and glucose or
fat metabolism in humans is fundamentally the same as ro-
dents. However, the molecular specificity may be different
between rodents and humans because both tOC and ucOC are
associated with glucose and fat metabolism in humans, while
ucOC was the candidate molecule in rodents. Although
vitamin K administration reduced ucOC, the increase in cOC
or tOC [24] may compensate for the decrease in ucOC in
humans. Thus, vitamin K intervention may not induce retar-
dation of glucose and fat metabolism through decreasing the
serum ucOC levels. The roles of vitamin K and osteocalcin on
various tissues are summarized in the Fig. 3.3.3. Undercarboxylated/uncarboxylated matrix Gla
protein (ucMGP)
3.3.1. Role of vitamin K metabolism in pseudoxanthoma
elasticum
A significant relationship between undercarboxylated
VKDs and tissue calcification has been observed in MGP
knockout mice [131]. These knockout mice suffered fromspontaneous and ultimately fetal calcification of arteries and
cartilage. The cause of soft-tissue calcification may result in
an imbalance of both systemic and tissue-specific inhibitors
and promoters of calcium precipitation in tissues such as
cartilage or vessels. Several candidate factors related to soft-
tissue calcification have been reported including fetuin-A
(a2-Schmid-Herrmans glycoprotein inhibitor) [132], MGP,
osteopontin [133], and bone morphogenetic protein-2 [134].
Proteins primarily involved in the regulation of bone calcifi-
cation, such as OC or osteonectin, have also been linked to
soft tissue calcification [130,135]. Among these regulators of
soft-tissue calcification, MGP is a key physiological inhibitor
of soft-tissue calcification. The activity of MGP as an inhibitor
of tissue calcification depends on two post-translational
modifications of the molecule. These include g-carboxyla-
tion, catalyzed by endoplasmic g-glutamyl carboxylase
(GGCX), and subsequent phosphorylation at a tandemly
repeated Ser-X-Glu sequence at the N-terminus [136].
Pseudoxanthoma elasticum (PXE) in humans is defined as a
dystrophic and progressive mineralization of elastic fibers in
cutaneous, ocular and vascular tissues. This autosomal reces-
sive multisystem disorder derives from a loss-of-function
mutation in the human ABCC6 (the large ATP-binding
cassette (ABC) gene subfamily C6) gene. This mutation was
found by positional cloning analysis [137]. The ABCC6 gene
encodes a 1503 amino acid transmembrane protein, ABCC6
(MRP6), which uses ATP hydrolysis to drive organic anion
transport across cellular membranes (efflux transporter) [138].
However, this finding raised an apparent dilemma concerning
the pathogenesis of PXE [137]. Because the ABCC6 protein is
mainly expressed in liver, how do mutations in the gene result
in mineralization of the skin, eyes, and blood vessels?
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intermittent claudication and muscle cramps in the legs and
arms. Hypertension, early occurrence of myocardial infarction
and gastro-intestinal bleeding are the other complications of
PXE. The vascular manifestations of PXE are caused by
degeneration of the elastic laminae of medium-size arteries
and excessive calcification. Since fragmentation of elastic fi-
bers and tissue calcification are the most predominant mani-
festations of PXE, one postulates that the disease revolves
around vitamin K dependent MGP. Gheduzzi et al. described
that PXE patients have a lower serum concentration of MGP
and a higher ratio of ucMGP [139] suggesting that modifier
gene(s) or environmental factors may be involved in tissue
calcification in PXE [140,141]. Since bleeding diathesis is
another clinical manifestation of PXE, deficiency of vitamin
K-dependent coagulation factor(s) may be attributed because
the ABCC6 mutation may induce retardation of vitamin K
transport to the liver. Serum levels of vitamin K1 in PXE or
PXE-like syndrome were reported to be significantly lower
than controls [142]. However, vitamin K administration in the
knockout animal model did not prevent vascular calcification
[141,143,144], although tissue vitamin K content was
increased [144]. Therefore, it was expected that the clinical
manifestations of PXE might result from an ABCC6 mutation
with vitamin K deficiency and also retardation of vitamin K
utilization. In this context, the functional abnormalities in
GGCX have been examined in a rodent model [144]. The soft-
tissue calcification of Abcc6//Ggcxþ/ double-mutant mice
was evaluated compared to Abcc//Ggcxþ/þ mice. The
Abcc//Ggcxþ/ mice had soft tissue calcification at a
younger age than the single-mutant counterparts. Furthermore,
the mineralization process was accelerated in Abcc//Ggcxþ/
 mice when the mice were fed a diet rich in phosphate (2-fold
higher than the control diet) and vitamin D3 (22-fold higher),
but low in calcium (25% of the control diet) and magnesium
(18%). These findings suggest a role for both the GGCX gene
as well as dietary factors in modulating the phenotypic
severity of PXE caused by loss-of-function mutations in
ABCC6 [144].
3.3.2. Vascular calcification and ucMGP
Vascular calcification is commonly observed in elderly
people and in patients with chronic hemodialysis, and
morbidity is associated with vascular accident through
atherosclerosis. Although the complete pathogenesis of
vascular calcification is not yet understood, multifactorial
processes are certainly involved in mineral apposition.
Currently, the efficacy of compounds such as bisphosphonates,
phosphate binders, selective vitamin D receptor activators or
calcium sensing receptor modulators [145] to prevent vascular
calcification in uremic patients has been investigated with the
caution of possible adverse events [146]. Vitamin K is also
postulated as a candidate to prevent vascular calcification
[147] because vitamin K activates MGP, which is a local
potent inhibitor of calcification in vessels [148]. Circulating
ucMGP is associated with vascular calcification [149] and
with vitamin K nutrition [150]. Vitamin K1 administrationslowed the progression of coronary artery calcification in
healthy older adults [150] and arterial calcification induced by
warfarin was reversible by high vitamin K intake in rats [151].
Therefore, the fortified intake of vitamin K may be a prom-
ising approach to prevent vascular calcification. Furthermore,
the measurement of ucMGP may have potential value for
identifying patients at high risk for developing cardiovascular
disease [152].3.4. Gas6Gas6 is the newest member of the family of vitamin K-
dependent proteins [153]. The structure of Gas6 is similar to
protein S and it functions as a growth factor-like molecule as it
interacts with receptor tyrosine kinases (RTKs) of the TAM
family (Tyrosine kinase receptors including TYRO3, AXL and
MERTK). The main role of Gas6, protein S and the TAM
receptors is the stimulation of cell proliferation and survival.
In addition, the Gas6-TAM system may also play roles in
inflammation, homeostasis of cultured cells, vascular diseases
such as thromboembolic disease, cancer and adiposity [153].
3.4.1. Gas6 and vascular disease
Gas6 is a growth-potentiating factor of vascular smooth
muscle cells (VSMCs) and one of the Gas6 receptors, Axl, was
cloned from rat carotid artery after mechanical damage. Both
Gas6 and Axl increased their expression in the damaged
vessels [153,154,155] in order to proliferate and migrate
VSMCs to recover the damaged area. Gas6/ mice were
protected against fetal thrombosis suggesting that the Gas6-
Axl system promotes platelet aggregation [2]. Since both
MGP and Gas6 are carboxylated within the vasculature,
warfarin inhibited the activation of MGP and Gas6 and
induced vascular calcification in animals [156] and in humans
[157]. Dietary intake of vitamin K2 was inversely related to
severe aortic calcification [158]. Serum levels of Gas6 at
admission were reported to be lower in patients with acute
coronary syndrome than in controls [159]. Gas6 gene poly-
morphisms were significantly associated with stroke [160].
Although warfarin treatment reduced carboxylation of Gas6,
there is no available data on whether ucGas6 can bind to TAM
receptors.
In general, vitamin K-dependent proteins such as MGP and
Gas6 are essential for the prevention of vascular calcification
through g-carboxylation of these molecules. Gas6 may
enhance platelet aggregation in vessels leading to vascular
embolism. Warfarin is used to prevent embolism, although it
carries a greater risk of bleeding, fracture and vascular calci-
fication through inhibition of activation of prothrombin, OC,
MGP and Gas6, respectively. Warfarin inhibition of carbox-
ylation of the Gas6 molecule may reduce hyper-aggregation of
platelets. Newly developed anti-coagulant drugs, such as
dabigatran, a direct thrombin inhibitor, and rivaroxaban, a
direct factor-Xa inhibitor, offer alternative treatments to
warfarin [87]. In fact, a randomized study showed that dabi-
gatran was more effective at reducing stroke and bleeding than
warfarin irrespective of INR (International Normalized Ratio)
Fig. 4. Gas6 and vitamin K regulate multicellular functions via the TAM re-
ceptor. Vitamin K activates Gas6 and protein S. Those two proteins commonly
bind to TAM receptor, which is localized ubiquitously, and displays subse-
quent variety biological functions. Gas6: growth arrest-specific protein-6,
TAM: tyrosine kinase receptors including TYRO3, Vit K: Vitamin K.
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may not develop vascular calcification because of the lack of
inhibition in g-carboxylation of MGP or Gas6. The benefits of
the new treatments are therefore obvious [161].
3.4.2. Role of Gas6 on systemic inflammation and insulin
resistance
Gas6 was originally found in growth-arrested fibroblasts
suggesting a role in protection from apoptosis. Gas6 expres-
sion is observed in many types of cells such as immune cells,
endothelial cells, vascular smooth muscle cells, and adipocytes
[162e164]. In addition to its role in vascular health, circu-
lating Gas6 protein levels are positively associated with
adiposity after adjustment for age, gender and other potential
confounders in adolescents [165]. Hsiao et al. simultaneously
reported a strong positive association between Gas6 levels and
the inflammatory marker, C-reactive protein (CRP), tumor
necrosis factor-a levels and insulin resistance in obese people
[165]. They utilized a polyclonal antibody for Gas6, which
meant that they could not distinguish ucGas6 and g-carbox-
ylated Gas6. This is particularly important because adoles-
cents may have a higher requirement for vitamin K to promote
sufficient g-carboxylation of VKD proteins.
According to the Framingham Offspring Cohort study, pro-
inflammatory cytokines such as IL-6, intercellular adhesion
molecule-1 (ICAM-1), and tumor necrosis factor receptor 2
(TNFR2) were negatively correlated with serum levels of
vitamin K1 and vitamin K intake [166]. The percentage of
ucOC was not associated with overall inflammation, but was
associated with CRP [166]. The same trend between CRP and
vitamin K deficiency (%ucOC) was also observed in an Asian
population [167]. The effect of vitamin K on inflammation is
transduced by TAM receptors, Tyro3, Axl and Mer, which also
are receptors for Gas6. In fact, TAM receptor activation by
Gas6 or protein S inhibited TLR (Toll-like receptor)-driven
cytokine production [168]. Therefore, the relationship be-
tween vitamin K and VKD proteins may play an important role
in autoimmune diseases. The Framingham cohort study
strongly suggested that sufficient vitamin K intake promotes
beneficial effects on the inflammation process. However, Gas6
levels showed a positive association with CRP and adiposity.
Gas6 deficient mice (Gas6/) had significantly reduced fat
mass than their WT counterparts when fed a high-fat diet [164].
The roles of vitamin K and/or VKD proteins on vascular
health and inflammation need further clarification. One
possible explanation for these controversies may depend on
the lack of information on vitamin K sufficiency and Gas6
measurements.
3.4.3. Vitamin K and Gas6 in the nervous system
A strong relationship between the K vitamins and sphin-
golipids in the brain was recognized 40 years ago. Among the
K vitamins, MK-4 was identified as the principal vitamin K in
brain. Certain sphingolipids in the brain are highly correlated
with MK-4 content suggesting that MK-4 plays an important
role on sphingolipids construction. A link between sphingoli-
pid metabolism and Alzheimer's disease [169] and Parkinson'sdisease [170] was recently reported. In addition, the discovery
of Gas6 and the characterization of its signaling actions in
neurons and various glial cell types through TAM receptors is
expected to have a relevant effect on cognition [171]. The
functions of Gas6 in various tissues are summarized in Fig. 4.
4. Interaction of vitamin K and vitamin D
Vitamins D and K are thought to be highly synergistic as
they both affect production and activation of osteocalcin
molecule in bone. Namely, vitamin D enhances gene expres-
sion of osteocalcin [172] and vitamin K activates osteocalcin
molecule through g-carboxylation, subsequently. In cell cul-
ture system, vitamin K addition to bone cells augmented a
vitamin D induced osteocalcin production [173] and both vi-
tamins may play an important role in extracellular minerali-
zation [173]. Therefore, the sufficiency of both vitamins may
have beneficial effects on bone health. Vitamin K deficiency
induced vascular calcification through under carboxylated
MGP production. On the other hand, vitamin D excess
induced vascular calcification. Thus, vitamin D toxicity and
vitamin K deficiency are similar in phenotype. It can be hy-
pothesized that vitamin K deficiency may enhance vitamin D
toxicity.
5. Summary of the clinical significance of vitamin K and
VKD proteins
Since vitamin K is considered to be a pleiotropic nutrient,
the functions of various tissues and systems are modified by
changes in vitamin K bioavailability. In this review, we indi-
cated five clinical topics, which need further elucidation, but
may open new therapeutic avenues in the clinical field:
1) DCP (PIVKA II) is associated with the progression and
metastasis of hepatocellular carcinoma (HCC) and the
measurement of DCP is useful to monitor the recurrence
of HCC. Although vitamin K administration failed to
inhibit the recurrence of HCC, the role of vitamin K
34 M. Shiraki et al. / Osteoporosis and Sarcopenia 1 (2015) 22e38nutrition on the occurrence of HCC has not yet been fully
investigated.
2) OC or ucOC are markers for bone formation and vitamin
K insufficiency in bone, respectively. Poor vitamin K
nutrition undoubtedly deteriorates bone health. Vitamin K
administration seemed to prevent incident fractures, but
the data are still insufficient to prove it. Vitamin K action
through SXR nuclear receptor activation needs more
clarification in patients.
3) OC and ucOC are both related to insulin secretion and
sensitivity aswell as secretion of fat cell cytokines in humans
and rodents. Although the molecular specificity between
humans (tOC) and rodents (ucOC) was different, the loop
between the bone, pancreas, and fat tissue may be of central
interest in the near future. The biological effects of OC may
extend not only to bone, but also to energy expenditure.
4) MGP is a potent inhibitor of vascular calcification. The
measurement of ucMGP is useful as a surrogate marker for
vascular calcification. Gas6, and its receptor complex, may
be a marker for vascular occlusion in the heart and central
nervous system. Whether vitamin K administration can
prevent vascular disease or not is still under investigation.
A larger scale prospective study will be required to reach a
definitive conclusion. The role of ucGas6 is still
completely unknown.
5) Numerous studies have shown that warfarin can prevent
embolism. However, the studies indicated that warfarin
treatment was associated with an increased risk of vascular
calcification, fractures and bleeding. Recent development
of anti-coagulants such as dabigatran or rivaroxaban has
shown that they prevent embolism. A comparative study
between warfarin and dabigatran clearly showed the ben-
efits of dabigatran in terms of prevention of stroke and
drug-induced bleeding.
6) Gas6, one of the VKD proteins, plays a role in inflam-
mation, homeostasis of cultured cells, vascular diseases
such as thromboembolic disease, cancer growth and signal
transduction in the brain. However, there have been no
tools to investigate the direct relationship between vitamin
K nutrition and the function of Gas6 because we could not
measure ucGas6.
7) Both vitamin K and D play an important role on bone
mineralization and vascular calcification. It may be
important to keep sufficient levels of these two vitamins
regarding bone and vascular health.Conflict of interest
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